The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > COMMENTARY
COMMENTARY
- Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
February 9, 2021
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
- Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
- Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
- IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
- Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
September 9, 2020
- COVID-19 Pandemic to Test True Value of MHLW’s Officers with Medical/Pharma Backgrounds
August 26, 2020
- COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
August 17, 2020
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
July 22, 2020
- Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
- Will Zolgensma Delay Spur Revision of Sakigake Designation System?
June 11, 2020
- Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
May 7, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
- Lenvima Heading into Megablockbuster Territory, Will Merck Tie-Up Help It Top Combined Aricept/Pariet Sales?
March 12, 2020
- Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
- Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
November 22, 2019
- Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms
November 18, 2019
- Pharma’s Downsizing Bandwagon Shows No Sign of Slowing, Companies Seeking Even Leaner Staff
October 28, 2019
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…